Seres Therapeutics
MCRB
72 hedge funds and large institutions have $243M invested in Seres Therapeutics in 2018 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 27 increasing their positions, 15 reducing their positions, and 10 closing their positions.
80% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 15
77% more call options, than puts
Call options by funds: $165K | Put options by funds: $93K
0.01% more ownership
Funds ownership: 3.91% → 3.92% (+0.01%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
8% less funds holding
Funds holding: 78 → 72 (-6)
11% less capital invested
Capital invested by funds: $274M → $243M (-$30.5M)
60% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$6.26M |
| 2 |
BlackRock
New York
|
+$329K |
| 3 |
JP Morgan Chase
New York
|
+$205K |
| 4 |
State Street
Boston,
Massachusetts
|
+$202K |
| 5 |
Renaissance Technologies
New York
|
+$200K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$3.13M |
| 2 |
Millennium Management
New York
|
-$1.27M |
| 3 |
SIM
Spark Investment Management
New York
|
-$633K |
| 4 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$455K |
| 5 |
CEP
Chicago Equity Partners
Chicago,
Illinois
|
-$227K |
MCRB Hedge Fund Activity: Q3 2018 in Review
72 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Seres Therapeutics (MCRB) for Q3 2018, worth a combined $243M — down 11% from $274M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of MCRB and 4 opened new positions — a net loss of 6 holders — while 15 trimmed existing stakes and 27 added.
The largest buyer was ARK Investment Management, adding an estimated $6.26M. The largest seller was Vanguard Group, cutting an estimated $3.13M.
- 72 institutional investors held Seres Therapeutics (MCRB) as of Q3 2018, down from 78 in Q2 2018.
- Funds reported $243M of Seres Therapeutics stock for Q3 2018, down 11% quarter-over-quarter.
- 4 funds opened new Seres Therapeutics positions in Q3 2018 and 10 closed out, a net change of -6 holders.
- The largest Seres Therapeutics buyer in Q3 2018 was ARK Investment Management, an estimated $6.26M added.
- The largest Seres Therapeutics seller in Q3 2018 was Vanguard Group, an estimated $3.13M sold.
Based on aggregated 13F filings for Q3 2018.